The Alzheimer's Association has established the Global Consortium for Biomarker Standardization to gather key researchers, clinicians, and industry, regulatory and government leaders in Alzheimer's disease to achieve consensus on the best ways to standardize and validate biomarker tests for use in clinical practices around the world.
About the Global Consortium
Global Biomarkers Standardization Consortium Face-to-Face
July 13-18, 2013
Contact Meredith.email@example.com for more information.
In the past few years, the Alzheimer's disease research enterprise has developed improved techniques and technologies aimed at early diagnosis and detection of Alzheimer's disease. The field has seen remarkable growth in research using clinical assessment, psychometric testing, cerebrospinal fluid-based biomarkers, magnetic resonance imaging (MRI) measurements of brain volume, and molecular imaging of beta-amyloid in the brain to diagnose Alzheimer's at its earliest stages.
Before these and other diagnostic measures can be incorporated into clinical practice worldwide, they must be standardized and validated on a global scale. The Global Consortium for Biomarker Standardization brings together these experts in teleconference and face-to-face meetings to address the challenges inherent in this goal and to develop the global scales required for worldwide implementation.
The Global Consortium for Biomarker Standardization will continue to grow and expand as the field identifies novel technologies and techniques for diagnosis of Alzheimer's disease. To date, there are projects addressing:
Meeting minutes and agendas
July 13-18, 2013
Boston, Massachusetts, USA
Related papers and abstracts
- Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S et al. Alzheimer's & Dementia. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. 2011 Jul; 7/(4): 386-395 e6.
- Blennow K, Hampel H, Weiner M, Zetterberg H. Nature Review Neurology. Cerebrospinal fluid and plasma biomarkers in Alzheimer's disease. 2010 Mar: 6(3): 131-44.
- Mattsson, Andreasson, Carrillo et al. Proficiency testing programs for Alzheimer’s disease cerebrospinal fluid biomarkers. Biomarkers M 404 ed. (2012) 6(4).
- Mattsson, Zegers, Andreasson et al. Reference measurement procedures for Alzheimer’s disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid b42Biomarkers Med. (2012) 6(4), 409–417.
For more information
For investigators who are interested in more information on the Global Consortium, including associated projects, past meetings or future meetings, please contact Maria C. Carrillo, Ph.D.
Maria C. Carrillo, Ph.D.
Vice President, Medical & Scientific Relations